$OXBR
Oxbridge Re Holdings Ltd Stock $oxbr

$oxbr Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223041028 Filed on November 14, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$584.0K	-$6.381M
YoY Change	-42.97%	816.81%
Cost Of Revenue
YoY Change
Gross Profit		-$6.381M
YoY Change
Gross Profit Margin
Selling, General & Admin	$475.0K	$628.0K
YoY Change	30.85%	94.43%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$1.000K	$5.000K
YoY Change	0.0%	-92.31%
% of Gross Profit
Operating Expenses	$767.0K	$688.0K
YoY Change	111.29%	-52.91%
Operating Profit		-$7.069M
YoY Change
Interest Expense	-$2.489M	-$7.004M
YoY Change	-14741.18%	53776.92%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.672M	-$7.069M
YoY Change	-494.1%	227.72%
Income Tax
% Of Pretax Income
Net Earnings	-$2.672M	-$7.300M
YoY Change	-494.1%	238.43%
Net Earnings / Revenue	-457.53%
Basic Earnings Per Share		$1.24
Diluted Earnings Per Share	-$0.46	$1.24
COMMON SHARES
Basic Shares Outstanding	5.870M shares	5.870M shares
Diluted Shares Outstanding		5.870M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$495.0K	$1.801M
Short-Term Investments
Other Short-Term Assets	$0.00	$0.00
YoY Change	-100.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$163.0K	$160.0K
YoY Change	-8.43%	1900.0%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.000K	$5.000K
YoY Change	-20.0%	-16.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$3.158M	$5.647M
YoY Change	-73.83%	-47.77%
Other Assets	$3.250M	$1.848M
YoY Change	19.44%	-15.19%
Total Long-Term Assets	$8.090M	$11.04M
YoY Change	-50.78%	-30.68%
TOTAL ASSETS
Total Short-Term Assets	$163.0K	$160.0K
Total Long-Term Assets	$8.090M	$11.04M
Total Assets	$8.253M	$11.20M
YoY Change	-50.33%	-29.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable
YoY Change
Accrued Expenses	$9.000K	$35.00K
YoY Change	-79.55%	-47.76%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$365.0K	$377.0K
YoY Change	7.99%	-73.69%
LONG-TERM LIABILITIES
Long-Term Debt	$118.0K	$118.0K
YoY Change	-45.37%	-45.37%
Other Long-Term Liabilities	$1.523M	$1.291M
YoY Change
Total Long-Term Liabilities	$1.641M	$1.409M
YoY Change	659.72%	552.31%
TOTAL LIABILITIES
Total Short-Term Liabilities	$365.0K	$377.0K
Total Long-Term Liabilities	$1.641M	$1.409M
Total Liabilities	$2.921M	$3.249M
YoY Change	79.53%	97.03%
SHAREHOLDERS EQUITY
Retained Earnings	-$27.41M	-$24.74M
YoY Change	56.66%	36.12%
Common Stock	$32.75M	$32.69M
YoY Change	0.79%	0.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$5.332M	$7.948M
YoY Change
Total Liabilities & Shareholders Equity	$8.253M	$11.20M
YoY Change	-50.33%	-29.71%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	-$2.672M	-$7.300M
YoY Change	-494.1%	238.43%
Depreciation, Depletion And Amortization	$1.000K	$5.000K
YoY Change	0.0%	-92.31%
Cash From Operating Activities	$96.00K	$254.0K
YoY Change	-165.31%	-222.71%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$5.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$100.0K
YoY Change	-100.0%
Cash From Investing Activities	$0.00	-$95.00K
YoY Change	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	2.000K
YoY Change
NET CHANGE
Cash From Operating Activities	96.00K	254.0K
Cash From Investing Activities	0.000	-95.00K
Cash From Financing Activities	0.000	2.000K
Net Change In Cash	96.00K	161.0K
YoY Change	-122.22%	-177.78%
FREE CASH FLOW
Cash From Operating Activities	$96.00K	$254.0K
Capital Expenditures	$0.00	-$5.000K
Free Cash Flow	$96.00K	$259.0K
YoY Change	-165.31%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001584831
CY2022Q4	us-gaap	Dividend And Interest Receivable DividendAndInterestReceivable		usd
CY2022Q4	us-gaap	Policy Loans Receivable PolicyLoansReceivable		usd
CY2022Q4	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts		usd
CY2022Q4	us-gaap	Unearned Premiums UnearnedPremiums		usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q3	OXBR	Losses Payable LossesPayable		usd
CY2023Q3	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned		usd
CY2022Q3	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned		usd
CY2023Q3	us-gaap	Ceded Premiums Earned CededPremiumsEarned		usd
CY2022Q3	us-gaap	Ceded Premiums Earned CededPremiumsEarned		usd
	us-gaap	Ceded Premiums Earned CededPremiumsEarned		usd
CY2023Q3	us-gaap	Insurance Agency Management Fee InsuranceAgencyManagementFee		usd
CY2022Q3	us-gaap	Insurance Agency Management Fee InsuranceAgencyManagementFee		usd
	us-gaap	Insurance Agency Management Fee InsuranceAgencyManagementFee		usd
CY2023Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2022Q3	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
CY2023Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses		usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses		usd
CY2022Q3	OXBR	Income Attributable To Noteholders And Tokenholders IncomeAttributableToNoteholdersAndTokenholders		usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses		usd
	us-gaap	Insurance Agency Management Fee InsuranceAgencyManagementFee		usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet		usd
	OXBR	Increase Decrease In Prepaid Offering Costs IncreaseDecreaseInPrepaidOfferingCosts		usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities		usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi		usd
	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable		usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt		usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2023Q3	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain		usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Realized Loss EquitySecuritiesFvNiRealizedLoss		usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain		usd
	us-gaap	Equity Securities Fv Ni Realized Loss EquitySecuritiesFvNiRealizedLoss		usd
CY2022Q3	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi		usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain		usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Realized Loss EquitySecuritiesFvNiRealizedLoss		usd
	us-gaap	Equity Securities Fv Ni Realized Loss EquitySecuritiesFvNiRealizedLoss		usd
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense		usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1		usd
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense		usd
CY2023Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2022Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants		shares
CY2023Q3	OXBR	Shares Issuable Upon Conversion Of Warrants SharesIssuableUponConversionOfWarrants		shares
CY2022Q3	OXBR	Shares Issuable Upon Conversion Of Warrants SharesIssuableUponConversionOfWarrants		shares
	OXBR	Shares Issuable Upon Conversion Of Warrants SharesIssuableUponConversionOfWarrants		shares
	OXBR	Shares Issuable Upon Conversion Of Warrants SharesIssuableUponConversionOfWarrants		shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q3	OXBR	Lessee Operating Lease Liability Payments Due After Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths		usd
CY2022Q4	OXBR	Lessee Operating Lease Liability Payments Due After Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueAfterNextTwelveMonths		usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	1-36346
	dei	Entity Registrant Name EntityRegistrantName	OXBRIDGE RE HOLDINGS LIMITED
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1150254
	dei	Entity Address Address Line1 EntityAddressAddressLine1	Suite 201
	dei	Entity Address Address Line2 EntityAddressAddressLine2	42 Edward Street, Georgetown
	dei	Entity Address Address Line3 EntityAddressAddressLine3	P.O. Box 469
	dei	Entity Address City Or Town EntityAddressCityOrTown	Grand Cayman
	dei	Entity Address Country EntityAddressCountry	KY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	KY1-9006
	dei	City Area Code CityAreaCode	(345)
	dei	Local Phone Number LocalPhoneNumber	749-7570
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5870234	shares
CY2023Q3	us-gaap	Equity Securities Fv Ni Cost EquitySecuritiesFvNiCost	1926000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	608000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	642000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1801000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1207000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1848000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2721000	usd
CY2023Q3	us-gaap	Dividend And Interest Receivable DividendAndInterestReceivable	13000	usd
CY2023Q3	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	1465000	usd
CY2022Q4	us-gaap	Premiums Receivable At Carrying Value PremiumsReceivableAtCarryingValue	282000	usd
CY2023Q3	us-gaap	Policy Loans Receivable PolicyLoansReceivable	100000	usd
CY2023Q3	us-gaap	Other Investments OtherInvestments	5039000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	11423000	usd
CY2023Q3	us-gaap	Other Receivables OtherReceivables	60000	usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables	45000	usd
CY2023Q3	us-gaap	Deferred Policy Acquisition Costs DeferredPolicyAcquisitionCosts	161000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	62000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	114000	usd
CY2022Q4	OXBR	Prepaid Offering Costs PrepaidOfferingCosts	133000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5000	usd
CY2023Q3	us-gaap	Assets Assets	11197000	usd
CY2022Q4	us-gaap	Assets Assets	16616000	usd
CY2023Q3	us-gaap	Unearned Premiums UnearnedPremiums	1463000	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1291000	usd
CY2023Q3	us-gaap	Notes Payable NotesPayable	118000	usd
CY2022Q4	us-gaap	Notes Payable NotesPayable	216000	usd
CY2022Q4	OXBR	Losses Payable LossesPayable	1073000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	35000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	44000	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	342000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities AccountsPayableAndOtherAccruedLiabilities	294000	usd
CY2023Q3	us-gaap	Liabilities Liabilities	3249000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	1627000	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5870234	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5870234	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5769587	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5769587	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6000	usd
CY2023Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	32684000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	32482000	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24742000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-17499000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7948000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14989000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11197000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16616000	usd
	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	2195000	usd
	us-gaap	Assumed Premiums Earned AssumedPremiumsEarned	705000	usd
	us-gaap	Ceded Premiums Earned CededPremiumsEarned	60000	usd
CY2023Q3	us-gaap	Premiums Written Net PremiumsWrittenNet	549000	usd
CY2022Q3	us-gaap	Premiums Written Net PremiumsWrittenNet	591000	usd
	us-gaap	Premiums Written Net PremiumsWrittenNet	-1463000	usd
	us-gaap	Premiums Written Net PremiumsWrittenNet	350000	usd
CY2023Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	549000	usd
CY2022Q3	us-gaap	Premiums Earned Net PremiumsEarnedNet	591000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	732000	usd
	us-gaap	Premiums Earned Net PremiumsEarnedNet	995000	usd
	us-gaap	Insurance Agency Management Fee InsuranceAgencyManagementFee	300000	usd
CY2023Q3	us-gaap	Net Investment Income NetInvestmentIncome	74000	usd
CY2022Q3	us-gaap	Net Investment Income NetInvestmentIncome	53000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	242000	usd
	us-gaap	Net Investment Income NetInvestmentIncome	128000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	27000	usd
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6889000	usd
CY2022Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-1327000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6384000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-986000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-115000	usd
CY2022Q3	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-13000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-34000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-355000	usd
CY2023Q3	us-gaap	Revenues Revenues	-6381000	usd
CY2022Q3	us-gaap	Revenues Revenues	-696000	usd
	us-gaap	Revenues Revenues	-5144000	usd
	us-gaap	Revenues Revenues	-191000	usd
CY2022Q3	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1073000	usd
	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1073000	usd
CY2023Q3	us-gaap	Foreign Reinsurance Transactions Expense Additions To Underwriting Balances ForeignReinsuranceTransactionsExpenseAdditionsToUnderwritingBalances	60000	usd
CY2022Q3	us-gaap	Foreign Reinsurance Transactions Expense Additions To Underwriting Balances ForeignReinsuranceTransactionsExpenseAdditionsToUnderwritingBalances	65000	usd
	us-gaap	Foreign Reinsurance Transactions Expense Additions To Underwriting Balances ForeignReinsuranceTransactionsExpenseAdditionsToUnderwritingBalances	80000	usd
	us-gaap	Foreign Reinsurance Transactions Expense Additions To Underwriting Balances ForeignReinsuranceTransactionsExpenseAdditionsToUnderwritingBalances	110000	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	628000	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	323000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1708000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1050000	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	688000	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	1461000	usd
	us-gaap	Operating Expenses OperatingExpenses	1788000	usd
	us-gaap	Operating Expenses OperatingExpenses	2233000	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-7069000	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2157000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-6932000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2424000	usd
CY2023Q3	OXBR	Income Attributable To Noteholders And Tokenholders IncomeAttributableToNoteholdersAndTokenholders	-231000	usd
	OXBR	Income Attributable To Noteholders And Tokenholders IncomeAttributableToNoteholdersAndTokenholders	-311000	usd
	OXBR	Income Attributable To Noteholders And Tokenholders IncomeAttributableToNoteholdersAndTokenholders	-43000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-7300000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2157000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7243000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2467000	usd
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.24
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.24
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.37
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5866083	shares
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5870234	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5870234	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5781587	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5781587	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5866083	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5866083	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5771506	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5771506	shares
	us-gaap	Net Income Loss NetIncomeLoss	-7243000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2467000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	202000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	96000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	5000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3000	usd
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	27000	usd
	us-gaap	Insurance Agency Management Fee InsuranceAgencyManagementFee	300000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6384000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-986000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-34000	usd
	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-355000	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	13000	usd
	us-gaap	Increase Decrease In Premiums Receivable IncreaseDecreaseInPremiumsReceivable	1183000	usd
	us-gaap	Increase Decrease In Premiums Receivable IncreaseDecreaseInPremiumsReceivable	286000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	15000	usd
	us-gaap	Increase Decrease In Due From Related Parties IncreaseDecreaseInDueFromRelatedParties	3000	usd
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	161000	usd
	us-gaap	Increase Decrease In Deferred Policy Acquisition Costs IncreaseDecreaseInDeferredPolicyAcquisitionCosts	-38000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-52000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	56000	usd
	OXBR	Increase Decrease In Prepaid Offering Costs IncreaseDecreaseInPrepaidOfferingCosts	-133000	usd
	OXBR	Increase Decrease In Reserve For Losses And Loss Adjustment Expenses IncreaseDecreaseInReserveForLossesAndLossAdjustmentExpenses	1073000	usd
	OXBR	Increase Decrease In Reserve For Losses And Loss Adjustment Expenses IncreaseDecreaseInReserveForLossesAndLossAdjustmentExpenses	-1073000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	311000	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	1463000	usd
	us-gaap	Increase Decrease In Unearned Premiums IncreaseDecreaseInUnearnedPremiums	-350000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	48000	usd
	us-gaap	Increase Decrease In Accounts Payable And Other Operating Liabilities IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities	-44000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1356000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-682000	usd
	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	1002000	usd
	us-gaap	Payments To Acquire Loans Receivable PaymentsToAcquireLoansReceivable	100000	usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	626000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-105000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-376000	usd
	us-gaap	Repayments Of Debt RepaymentsOfDebt	98000	usd
	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	1280000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1182000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-279000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1058000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3928000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	5418000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3649000	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4360000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	16651000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-387000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	16296000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	77000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16405000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2157000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	32000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	14280000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14989000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	142000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	54000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	15185000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-85000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	55000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	15155000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	15155000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-7300000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-7300000	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	93000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7948000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	7948000	usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5771506	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.24
	OXBR	Prepaid Offering Cost PrepaidOfferingCost	133000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-2467000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5870234	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5781587	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5866083	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5771506	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5870234	shares
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z6LeMhgm4cg6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><b><span style="text-decoration: underline"><span id="xdx_86E_zYqtKE66iR62">Reclassifications</span>: </span></b>Any reclassifications of prior period amounts have been made to conform to the current period presentation.</span></p>
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1801000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	1207000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1848000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2721000	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3649000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	3928000	usd
	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	626000	usd
	us-gaap	Equity Securities Fv Ni Realized Gain EquitySecuritiesFvNiRealizedGain	27000	usd
CY2021Q3	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	2000000	usd
CY2021Q3	OXBR	Capital Risk Percentage CapitalRiskPercentage	0.347	pure
CY2021Q3	OXBR	Ordinary Shares Percentage OrdinarySharesPercentage	0.496	pure
CY2021Q3	OXBR	Preferred Shares Percentage PreferredSharesPercentage	0.631	pure
	OXBR	Fair Value Measurements Description FairValueMeasurementsDescription	The fair value calculation of the Company’s beneficial interest in JetAI’s ordinary shares and public warrants is dependent on the observable trading prices of JetAI’s Class A shares and public warrants. The fair value of of the Company’s beneficial interest in the Extension Loan is estimated to be the pro-rata original principal amount of the Extension Loan due to the short-term nature.
CY2023Q3	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6889000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6384000	usd
CY2023Q3	us-gaap	Other Investments OtherInvestments	5039000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	11423000	usd
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	-6384000	usd
CY2023Q3	us-gaap	Other Investments OtherInvestments	5039000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1801000	usd
CY2023Q3	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1848000	usd
CY2023Q3	us-gaap	Other Investments OtherInvestments	5039000	usd
CY2023Q3	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	608000	usd
CY2023Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	9296000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	1207000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2721000	usd
CY2022Q4	us-gaap	Other Investments OtherInvestments	11423000	usd
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	642000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	15993000	usd
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5781587	shares
	us-gaap	Repayments Of Debt RepaymentsOfDebt	98000	usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	118000	usd
	us-gaap	Underwriting Income Loss UnderwritingIncomeLoss	282000000	usd
	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<p id="xdx_890_eus-gaap--ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_z6qnoO2fgu1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The following table summarizes the Company’s loss and loss adjustment expenses (“LAE”) and the reserve for loss and LAE reserve movements for the nine-month periods ending September 30, 2023 and 2022:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BE_zhyS2P4Mjrn5" style="display: none">SCHEDULE OF LOSS ADJUSTMENT EXPENSE</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_496_20230101__20230930_zC7GPP2Q7N92" style="text-align: center; font-weight: bold">At </td><td style="text-align: center; font-weight: bold"> </td><td style="text-align: center; font-weight: bold"> </td> <td colspan="2" id="xdx_493_20220101__20220930_zh9sYGtS2Hv" style="text-align: center; font-weight: bold">At</td><td style="text-align: center; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="text-align: center; font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">September 30, 2023</td><td style="text-align: center; padding-bottom: 1.5pt; font-weight: bold"> </td><td style="text-align: center; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>September 30, 2022</b></span></td><td style="text-align: center; padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="text-align: center; font-weight: bold">(in thousands)</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_402_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpense_iS_pn3n3_z4vabrY3r4Ge" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 52%">Balance, beginning of period</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right">1,073</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 20%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0827">-</span></td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Incurred related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_pn3n3_maLFUCAzKTv_z2zfHm4hxkHc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Current period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0829">-</span></td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,073</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_pn3n3_maLFUCAzKTv_zY7uUQlU7ts9" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Prior period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0832">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0833">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_iT_pn3n3_mtLFUCAzKTv_zk3GoXBjmFo5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total incurred</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0835">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,073</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Paid related to:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_iN_pn3n3_di_maPFLALzSy6_zI57NQ6shhu7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Current period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><p style="margin: 0"><span style="-sec-ix-hidden: xdx2ixbrl0838">-</span></p></td><td style="text-align: left"></td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0839">-</span></td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_iN_pn3n3_di_maPFLALzSy6_zPjv4Mq4rlR4" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt; padding-left: 10pt">Prior period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,073</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0842">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--PaymentsForLossesAndLossAdjustmentExpense_iNT_pn3n3_di_mtPFLALzSy6_z3J1p42n0pdc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total paid</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,073</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0845">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--LiabilityForClaimsAndClaimsAdjustmentExpense_iE_pn3n3_zxXtoGYoQCSi" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Balance, end of period</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0847">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"></td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,073</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p>
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1073000	usd
	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	1073000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	1073000	usd
	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	1073000	usd
	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	1073000	usd
CY2022Q3	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	1073000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-7300000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-2157000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7243000	usd
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.37
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.24
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.37
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.23
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.43
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1	P10Y
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	871250	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.67
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y7M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	25000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	6.00
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	846250	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.63
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y6M
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	736875	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.43
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y2M12D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	846250	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.63
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y3M18D
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	752500	shares
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.46
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	846250	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.63
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	768125	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.49
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P4Y9M3D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	896250	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.71
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M24D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	896250	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.71
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y7M6D
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	601250	shares
CY2022Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.44
CY2022Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y8M12D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	896250	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.71
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y4M24D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	641250	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.42
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y7M6D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	896250	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.71
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y1M20D
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	681250	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	4.41
CY2022Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y6M
CY2023Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	25000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	71000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	23000	shares
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	100647	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.37
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	32750	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.37
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	90897	shares
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.37
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	32324	shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	2.37
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	58573	shares
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.37
	OXBR	Statutory Accounting Practice Statutory Capital And Surplus Required StatutoryAccountingPracticeStatutoryCapitalAndSurplusRequired	Under the terms of their respective licenses, Oxbridge Reinsurance Limited and Oxbridge Re NS are required to maintain a minimum and prescribed capital requirement of $500 in accordance with the relevant subsidiary’s approved business plan filed with CIMA
	us-gaap	Operating Lease Cost OperatingLeaseCost	76000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	72000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	76000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	72000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	44000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	35000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	44000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y4M13D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y2M1D
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0762	pure
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0650	pure
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	26000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	40000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	9000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	35000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	46000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	2000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	35000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	44000	usd
CY2023Q3	us-gaap	Debt Instrument Description DebtInstrumentDescription	Notes with 100% of the proceeds of any equity or debt financing at a redemption premium of 110% of the principal amount of the Notes
CY2023Q3	us-gaap	Policy Loans Receivable PolicyLoansReceivable	100000	usd

Files In Submission

Name	View Source	Status
oxbr-20230930_cal.xml	Edgar Link	unprocessable
0001493152-23-041028-index-headers.html	Edgar Link	pending
0001493152-23-041028-index.html	Edgar Link	pending
0001493152-23-041028.txt	Edgar Link	pending
0001493152-23-041028-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
oxbr-20230930.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
oxbr-20230930_lab.xml	Edgar Link	unprocessable
oxbr-20230930_pre.xml	Edgar Link	unprocessable
oxbr-20230930_def.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OXBR
Oxbridge Re Holdings Ltd Stock $oxbr

2023 Q4 Form 10-Q Financial Statement

#000149315223041028 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OXBR Oxbridge Re Holdings Ltd Stock $oxbr

2023 Q4 Form 10-Q Financial Statement

#000149315223041028 Filed on November 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OXBR
Oxbridge Re Holdings Ltd Stock $oxbr